NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
Celgene
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Dana-Farber Cancer Institute
Genentech, Inc.
University of Sao Paulo